NEW HAVEN, Conn. — August 13, 2025 — Leads & Copy — BioXcel Therapeutics, Inc. (Nasdaq: BTAI) announced that CEO Vimal Mehta, Ph.D., will participate in a virtual fireside chat on Thursday, August 14, 2025, at 1:00 p.m. ET as part of the H.C. Wainwright & Co. “HCW@Home” series. The biopharmaceutical company utilizes artificial intelligence to develop transformative medicines in neuroscience.
The event will be webcast live; registration details are available via the provided link.
About BioXcel Therapeutics, Inc.: BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications.
Contact Information:
Corporate/Investors:
Nic Johnson
Russo Partners
nic.johnson@russopartnersllc.com
1.303.482.6405
Media:
David Schull
Russo Partners
david.schull@russopartnersllc.com
1.858.717.2310
Source: BioXcel Therapeutics, Inc.
